Haemorrhoids are recognized as one of the most common medical conditions in general population, effecting up to 33% of the population under the age of 50 and up to 50% of the global population aged over 50. Haemorrhoid cushions are naturally occurring vascular structures present in the anal canal that contribute to air and liquid control and prevention of incontinence. However, in haemorrhoids disease, these structures become swollen, most commonly when the mucosa falls down from its normal position. This causes pain, soiling, itching, soreness and bleeding, reducing the patients quality of life. Currently available surgical treatments are associated with postoperative pain, high frequency of relapse, stenosis (narrowing of rectum), faecal or air incontinence and long recovery time (up to 1 month). In severe cases, surgery is the only option. Modern surgical treatments focus on preserving and restoring the haemorrhoids, however they are expensive and not affordable for all the affected population.
Developeration AB is a Swedish medical device company founded in 2016 by CEO Dr. Johan Ungerstedt. The company aims to provide innovative solutions for medical and surgical application, in order to improve outcomes, reduce complications and lower costs. Currently, Developeration is focused on helping patients suffering with haemorrhoids through a new innovative device, PexyEazy®, for the surgical treatment of haemorrhoids. Developeration AB has developed a novel, simple-to-use medical device based on modern methods of treating haemorrhoids disease, while preserving the natural function of the haemorrhoid cushions. They key development and commercialization objectives are to manufacture PexyEazy® for clinical study, preclinical validation and clinical studies. To obtain CE mark. Developeration undertook the feasibility study to determine whether the PexyEazy® device and business model were scalable, cost-effective and profitable, and to identify any strengths and weaknesses moving forward.
